tiprankstipranks
Probiotec Limited (DE:PG3)
BERLIN:PG3

Probiotec Limited (PG3) Stock Price & Analysis

0 Followers

PG3 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€1.28 - €1.77
Previous Close€1.75
Volume0.00
Average Volume (3M)N/A
Market Cap
€144.78M
Enterprise Value€188.16M
Total Cash (Recent Filing)AU$22.20M
Total Debt (Recent Filing)AU$92.99M
Price to Earnings (P/E)N/A
Beta0.21
Aug 21, 2024
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding81,323,406
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.14
R-Squared0.08
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

PG3 FAQ

What was Probiotec Limited’s price range in the past 12 months?
Probiotec Limited lowest stock price was €1.28 and its highest was €1.77 in the past 12 months.
    What is Probiotec Limited’s market cap?
    Currently, no data Available
    When is Probiotec Limited’s upcoming earnings report date?
    Probiotec Limited’s upcoming earnings report date is Aug 21, 2024 which is in 97 days.
      How were Probiotec Limited’s earnings last quarter?
      Probiotec Limited released its earnings results on Feb 27, 2024. The company reported €0.045 earnings per share for the quarter, the consensus estimate of €0.045 by €0.
        Is Probiotec Limited overvalued?
        According to Wall Street analysts Probiotec Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Probiotec Limited pay dividends?
          Probiotec Limited pays a Annually dividend of €0.02 which represents an annual dividend yield of N/A. See more information on Probiotec Limited dividends here
            What is Probiotec Limited’s EPS estimate?
            Probiotec Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Probiotec Limited have?
            Currently, no data Available
            What happened to Probiotec Limited’s price movement after its last earnings report?
            Probiotec Limited reported an EPS of €0.045 in its last earnings report, expectations of €0.045. Following the earnings report the stock price went down -1.235%.
              Which hedge fund is a major shareholder of Probiotec Limited?
              Currently, no hedge funds are holding shares in DE:PG3
              ---

              Company Description

              Probiotec Limited

              Probiotec Ltd is engaged in manufacturing, marketing, and distributing over-the-counter pharmaceuticals, complementary medicines, and specialty ingredients. It operates through the contract manufacturing segment. It is engaged in manufacture and packing plant producing predominantly pharmaceutical products along with cosmetics and consumer health products.
              ---

              PG3 Stock 12 Month Forecast

              Average Price Target

              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2022","6":"Dec<br/>2022","9":"Mar<br/>2023","12":"May<br/>2023","25":"May<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,1.4123076923076923,1.2946153846153847,1.176923076923077,1.0592307692307692,0.9415384615384615,0.8238461538461539,0.7061538461538461,0.5884615384615385,0.47076923076923083,0.35307692307692307,0.2353846153846153,0.11769230769230776,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,1.4123076923076923,1.2946153846153847,1.176923076923077,1.0592307692307692,0.9415384615384615,0.8238461538461539,0.7061538461538461,0.5884615384615385,0.47076923076923083,0.35307692307692307,0.2353846153846153,0.11769230769230776,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,1.4123076923076923,1.2946153846153847,1.176923076923077,1.0592307692307692,0.9415384615384615,0.8238461538461539,0.7061538461538461,0.5884615384615385,0.47076923076923083,0.35307692307692307,0.2353846153846153,0.11769230769230776,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.43,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.33,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.45,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.41,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.38,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.32,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.38,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.34,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.39,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.38,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.38,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.53,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Volati AB
              Medical Developments International Limited
              Recce Pharmaceuticals Ltd.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis